A patient aged 12 years or older develops a rash three days after a single dose of baloxavir; how should this be managed?

Management of Rash Following Baloxavir Administration

A rash developing 3 days after baloxavir in a patient ≥12 years should prompt immediate clinical assessment to distinguish between mild cutaneous reactions (which may be managed conservatively with antihistamines and monitoring) versus serious hypersensitivity reactions requiring drug discontinuation.

Initial Assessment

The timing (3 days post-dose) and presentation are critical. According to the AAP guidelines, hypersensitivity reactions, including anaphylaxis, have been reported postmarketing with baloxavir 1. The FDA label confirms this risk 2.

Classify the Reaction Severity:

Mild cutaneous reactions:

• Localized rash without systemic symptoms
• No mucosal involvement
• No respiratory or hemodynamic compromise

Serious reactions requiring immediate discontinuation:

• Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
• Drug rash with eosinophilia and systemic symptoms (DRESS)
• Anaphylaxis or anaphylactic shock
• Mucosal involvement
• Fever, lymphadenopathy, or organ involvement

Management Algorithm

For Mild Cutaneous Reactions:

1. Symptomatic management with antihistamines (H1-blockers) for pruritus
2. Close monitoring for progression over 24-48 hours
3. Patient education about warning signs requiring immediate medical attention
4. No further baloxavir doses (since it's a single-dose medication, this is already complete)

For Serious Hypersensitivity Reactions:

1. Immediately discontinue any ongoing exposure
2. Initiate appropriate emergency management based on severity:
   • Anaphylaxis: epinephrine, IV fluids, airway management
   • SJS/TEN: hospitalization, supportive care, dermatology consultation
   • DRESS: systemic corticosteroids, hospitalization
3. Document the reaction clearly in medical records
4. Permanent contraindication to baloxavir for future use

Important Clinical Considerations

Common adverse events with baloxavir listed in guidelines include nausea, vomiting, and diarrhea—not typically rash 1. However, the FDA label and postmarketing surveillance confirm hypersensitivity reactions do occur 2.

Recent pharmacovigilance data identified drug eruption and anaphylactic reactions as robust safety signals with baloxavir 3. The same analysis found that rash, urticaria, and erythema multiforme signals disappeared during sensitivity analyses, suggesting these may be false positives or confounded by other factors 3.

Do not use prophylactic corticosteroids or antihistamines at the time of drug initiation, as this approach has not proven effective and may mask early warning signs of serious reactions 4, 5.

Alternative Antiviral Options

If future influenza treatment is needed and the rash was determined to be drug-related:

• Oseltamivir is the preferred alternative (75 mg twice daily for 5 days in patients ≥40 kg) 1
• Zanamivir (inhaled) is another option if no contraindications exist 1
• Cross-reactivity between baloxavir and neuraminidase inhibitors is not expected as they target different viral proteins 2

Key Pitfalls to Avoid

• Do not rechallenge with baloxavir if a serious hypersensitivity reaction occurred
• Do not dismiss mild rashes without proper follow-up, as they may progress
• Do not confuse common GI side effects (nausea, vomiting, diarrhea) with hypersensitivity reactions
• Document clearly whether the reaction was mild or serious to guide future antiviral selection